Literature DB >> 32534635

Triple therapy for BRAFV600-mutated melanoma.

Antoni Ribas1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32534635      PMCID： PMC8063890          DOI： 10.1016/S0140-6736(20)31285-X

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  11 in total

Review 1.  Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges.

Authors:  Siwen Hu-Lieskovan; Lidia Robert; Blanca Homet Moreno; Antoni Ribas
Journal:  J Clin Oncol       Date:  2014-06-23       Impact factor: 44.544

2.  Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.

Authors:  Siwen Hu-Lieskovan; Stephen Mok; Blanca Homet Moreno; Jennifer Tsoi; Lidia Robert; Lucas Goedert; Elaine M Pinheiro; Richard C Koya; Thomas G Graeber; Begoña Comin-Anduix; Antoni Ribas
Journal:  Sci Transl Med       Date:  2015-03-18       Impact factor: 17.956

3.  Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.

Authors:  Caroline Robert; Antoni Ribas; Jacob Schachter; Ana Arance; Jean-Jacques Grob; Laurent Mortier; Adil Daud; Matteo S Carlino; Catriona M McNeil; Michal Lotem; James M G Larkin; Paul Lorigan; Bart Neyns; Christian U Blank; Teresa M Petrella; Omid Hamid; Shu-Chih Su; Clemens Krepler; Nageatte Ibrahim; Georgina V Long
Journal:  Lancet Oncol       Date:  2019-07-22       Impact factor: 41.316

4.  Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

Authors:  Caroline Robert; Jean J Grob; Daniil Stroyakovskiy; Boguslawa Karaszewska; Axel Hauschild; Evgeny Levchenko; Vanna Chiarion Sileni; Jacob Schachter; Claus Garbe; Igor Bondarenko; Helen Gogas; Mario Mandalá; John B A G Haanen; Celeste Lebbé; Andrzej Mackiewicz; Piotr Rutkowski; Paul D Nathan; Antoni Ribas; Michael A Davies; Keith T Flaherty; Paul Burgess; Monique Tan; Eduard Gasal; Maurizio Voi; Dirk Schadendorf; Georgina V Long
Journal:  N Engl J Med       Date:  2019-06-04       Impact factor: 91.245

5.  Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

Authors:  James S Wilmott; Georgina V Long; Julie R Howle; Lauren E Haydu; Raghwa N Sharma; John F Thompson; Richard F Kefford; Peter Hersey; Richard A Scolyer
Journal:  Clin Cancer Res       Date:  2011-12-12       Impact factor: 12.531

6.  Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma.

Authors:  Antoni Ribas; Adil Daud; Anna C Pavlick; Rene Gonzalez; Karl D Lewis; Omid Hamid; Thomas F Gajewski; Igor Puzanov; Matthew Wongchenko; Isabelle Rooney; Jessie J Hsu; Yibing Yan; Erica Park; Grant A McArthur
Journal:  Clin Cancer Res       Date:  2019-11-15       Impact factor: 12.531

Review 7.  Targeted agents and immunotherapies: optimizing outcomes in melanoma.

Authors:  Jason J Luke; Keith T Flaherty; Antoni Ribas; Georgina V Long
Journal:  Nat Rev Clin Oncol       Date:  2017-04-04       Impact factor: 66.675

8.  Host immunity contributes to the anti-melanoma activity of BRAF inhibitors.

Authors:  Deborah A Knight; Shin Foong Ngiow; Ming Li; Tiffany Parmenter; Stephen Mok; Ashley Cass; Nicole M Haynes; Kathryn Kinross; Hideo Yagita; Richard C Koya; Thomas G Graeber; Antoni Ribas; Grant A McArthur; Mark J Smyth
Journal:  J Clin Invest       Date:  2013-02-01       Impact factor: 14.808

9.  Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Ralf Gutzmer; Daniil Stroyakovskiy; Helen Gogas; Caroline Robert; Karl Lewis; Svetlana Protsenko; Rodrigo P Pereira; Thomas Eigentler; Piotr Rutkowski; Lev Demidov; Georgy Moiseevich Manikhas; Yibing Yan; Kuan-Chieh Huang; Anne Uyei; Virginia McNally; Grant A McArthur; Paolo A Ascierto
Journal:  Lancet       Date:  2020-06-13       Impact factor: 79.321

10.  Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.

Authors:  Marcel A Deken; Jules Gadiot; Ekaterina S Jordanova; Ruben Lacroix; Melissa van Gool; Paula Kroon; Cristina Pineda; Marnix H Geukes Foppen; Richard Scolyer; Ji-Ying Song; Inge Verbrugge; Christoph Hoeller; Reinhard Dummer; John B A G Haanen; Georgina V Long; Christian U Blank
Journal:  Oncoimmunology       Date:  2016-10-14       Impact factor: 8.110
View more
  1 in total

Review 1.  Signal pathways of melanoma and targeted therapy.

Authors:  Weinan Guo; Huina Wang; Chunying Li
Journal:  Signal Transduct Target Ther       Date:  2021-12-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.